Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMEA NASDAQ:ETHZ NASDAQ:FTLF NASDAQ:NEUP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMEABiomea Fusion$1.17-1.7%$1.55$0.87▼$3.08$84.59M-0.311.10 million shs609,693 shsETHZFlag Ship Acquisition$5.35+1.1%$4.07$0.70▼$17.46$101.71M1.176.44 million shs300,160 shsFTLFFitLife Brands$11.01-4.9%$9.85$8.67▼$20.98$103.40M0.0228,820 shs20,987 shsNEUPNeuphoria Therapeutics$4.45-0.9%$4.92$3.64▼$21.40$23.62M0.7267,808 shs42,992 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMEABiomea Fusion-1.68%-7.87%-20.95%-13.97%-53.20%ETHZFlag Ship Acquisition-4.34%+6.44%+18.34%+83.04%+528,999,900.00%FTLFFitLife Brands-4.92%+11.55%+15.53%-20.28%-20.68%NEUPNeuphoria Therapeutics-0.89%-0.89%-10.64%-1.98%-37.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMEABiomea Fusion$1.17-1.7%$1.55$0.87▼$3.08$84.59M-0.311.10 million shs609,693 shsETHZFlag Ship Acquisition$5.35+1.1%$4.07$0.70▼$17.46$101.71M1.176.44 million shs300,160 shsFTLFFitLife Brands$11.01-4.9%$9.85$8.67▼$20.98$103.40M0.0228,820 shs20,987 shsNEUPNeuphoria Therapeutics$4.45-0.9%$4.92$3.64▼$21.40$23.62M0.7267,808 shs42,992 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMEABiomea Fusion-1.68%-7.87%-20.95%-13.97%-53.20%ETHZFlag Ship Acquisition-4.34%+6.44%+18.34%+83.04%+528,999,900.00%FTLFFitLife Brands-4.92%+11.55%+15.53%-20.28%-20.68%NEUPNeuphoria Therapeutics-0.89%-0.89%-10.64%-1.98%-37.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMEABiomea Fusion 2.75Moderate Buy$8.50626.50% UpsideETHZFlag Ship Acquisition 1.00SellN/AN/AFTLFFitLife Brands 2.25Hold$21.5095.28% UpsideNEUPNeuphoria Therapeutics 2.00Hold$21.00371.91% UpsideCurrent Analyst Ratings BreakdownLatest NEUP, ETHZ, FTLF, and BMEA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2026FTLFFitLife Brands Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)6/1/2026NEUPNeuphoria Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/15/2026NEUPNeuphoria Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral5/5/2026BMEABiomea Fusion CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy ➝ Outperform5/5/2026BMEABiomea Fusion Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$9.004/28/2026BMEABiomea Fusion D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.004/20/2026BMEABiomea Fusion Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/8/2026BMEABiomea Fusion D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.004/7/2026FTLFFitLife Brands Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/2/2026FTLFFitLife Brands Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$21.00 ➝ $18.003/27/2026BMEABiomea Fusion CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$6.00 ➝ $7.00(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMEABiomea FusionN/AN/AN/AN/A$0.42 per shareN/AETHZFlag Ship Acquisition$4.11M24.75N/AN/A$29.12 per share0.18FTLFFitLife Brands$81.46M1.27$1.17 per share9.44$4.65 per share2.37NEUPNeuphoria Therapeutics$15.65M1.54$0.16 per share28.04$10.11 per share0.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMEABiomea Fusion-$61.80M-$0.68N/AN/AN/AN/A-265.37%-103.96%8/4/2026 (Estimated)ETHZFlag Ship Acquisition-$6.17M-$159.65N/AN/AN/AN/A-185.71%-83.12%N/AFTLFFitLife Brands$6.33M$0.6013.949.57N/A6.64%18.31%8.21%N/ANEUPNeuphoria Therapeutics-$370K-$11.06N/AN/AN/AN/A-76.93%-54.76%N/ALatest NEUP, ETHZ, FTLF, and BMEA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q3 2026NEUPNeuphoria Therapeutics-$0.56-$0.09+$0.47-$0.09N/AN/A5/14/2026Q1 2026FTLFFitLife Brands$0.14$0.17+$0.03$0.17N/A$25.33 million5/11/2026Q1 2026BMEABiomea Fusion-$0.24-$0.17+$0.07-$0.17N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBMEABiomea FusionN/AN/AN/AN/AN/AETHZFlag Ship AcquisitionN/AN/AN/AN/AN/AFTLFFitLife BrandsN/AN/AN/AN/AN/ANEUPNeuphoria TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMEABiomea FusionN/A4.984.98ETHZFlag Ship Acquisition1.1110.0710.07FTLFFitLife Brands0.781.520.49NEUPNeuphoria TherapeuticsN/A14.3114.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMEABiomea Fusion96.72%ETHZFlag Ship Acquisition4.07%FTLFFitLife Brands2.32%NEUPNeuphoria Therapeutics15.90%Insider OwnershipCompanyInsider OwnershipBMEABiomea Fusion10.60%ETHZFlag Ship Acquisition15.10%FTLFFitLife Brands61.40%NEUPNeuphoria Therapeutics1.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMEABiomea Fusion5072.30 million64.64 millionOptionableETHZFlag Ship Acquisition719.01 million16.14 millionN/AFTLFFitLife Brands209.39 million3.63 millionNot OptionableNEUPNeuphoria TherapeuticsN/A5.40 million5.32 millionN/ANEUP, ETHZ, FTLF, and BMEA HeadlinesRecent News About These CompaniesReviewing Neuphoria Therapeutics (NASDAQ:NEUP) and Psyence Biomedical (NASDAQ:PBM)June 6, 2026 | americanbankingnews.comHC Wainwright & Co. downgrades Neuphoria Therapeutics (NEUP)May 17, 2026 | msn.comNeuphoria Therapeutics (NEUP) price target increased by 38.22% to 13.77May 14, 2026 | msn.comHere's Why We're Not At All Concerned With Neuphoria Therapeutics' (NASDAQ:NEUP) Cash Burn SituationFebruary 19, 2026 | uk.finance.yahoo.comNeuphoria Therapeutics (NEUP) price target decreased by 32.33% to 9.96December 22, 2025 | msn.comLeading Advisory Firms Recommend Voting FOR Lynx1's Independent NomineesDecember 8, 2025 | marketwatch.comLeading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director NomineesDecember 8, 2025 | markets.businessinsider.comLeading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director NomineesDecember 8, 2025 | globenewswire.comHC Wainwright & Co. maintains Neuphoria Therapeutics (NEUP) buy recommendationDecember 5, 2025 | msn.comNeuphoria Therapeutics price target lowered to $7 from $21 at HC WainwrightDecember 5, 2025 | msn.comNeuphoria Therapeutics responds to Lynx1’s revised indication of interestDecember 4, 2025 | msn.comNeuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and PremiumDecember 4, 2025 | finance.yahoo.comNeuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and PremiumDecember 4, 2025 | globenewswire.comLynx1 Sends Open Letter to Fellow Neuphoria ShareholdersDecember 3, 2025 | finance.yahoo.comNeuphoria Therapeutics ‘exposes false narratives’ responding to Lynx1December 1, 2025 | msn.comNeuphoria Therapeutics Inc. Responds to Allegations from Lynx1 Master Fund LP, Urges Stockholders to Support Its NomineesDecember 1, 2025 | quiverquant.comQNeuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 FictionsDecember 1, 2025 | globenewswire.comNeuphoria Therapeutics urges stockholders to vote for company nomineesNovember 24, 2025 | msn.comNeuphoria Therapeutics Inc. Sends Letter to StockholdersNovember 24, 2025 | globenewswire.comNeuphoria Therapeutics (NEUP) Price Target Decreased by 25.73% to 14.72November 17, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 2026Alphabet Just Unveiled Its Most Ambitious AI Lineup YetBy Ryan Hasson | May 26, 2026NEUP, ETHZ, FTLF, and BMEA Company DescriptionsBiomea Fusion NASDAQ:BMEA$1.17 -0.02 (-1.68%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$1.19 +0.02 (+1.71%) As of 06/12/2026 06:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.Flag Ship Acquisition NASDAQ:ETHZ$5.35 +0.06 (+1.13%) As of 06/12/20261180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.FitLife Brands NASDAQ:FTLF$11.01 -0.57 (-4.92%) Closing price 06/12/2026 04:00 PM EasternExtended Trading$10.76 -0.25 (-2.26%) As of 06/12/2026 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.Neuphoria Therapeutics NASDAQ:NEUP$4.45 -0.04 (-0.89%) Closing price 06/12/2026 03:58 PM EasternExtended Trading$4.43 -0.02 (-0.45%) As of 06/12/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution TJX: Retail’s Apex Predator Feasts on Inflation Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears This Energy Stock Has Quietly Soared 130% in a Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
